Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
6.12
+0.96 (18.72%)
At close: Aug 28, 2026, 4:00 PM EDT
5.70
-0.42 (-6.86%)
After-hours: Aug 28, 2026, 7:59 PM EDT

Quoin Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.716.495.936.076.584.5
Research & Development
12.449.83.63.312.671.56
Operating Expenses
19.1516.299.539.389.266.06
Operating Income
-19.15-16.29-9.53-9.38-9.26-6.06
Interest Expense
-----0.71-1.37
Interest & Investment Income
0.480.480.560.690.1-
Other Non Operating Income (Expenses)
-000.01-00.08-12.78
EBT Excluding Unusual Items
-18.67-15.8-8.96-8.69-9.8-20.21
Other Unusual Items
----0.42-1.25
Pretax Income
-18.67-15.8-8.96-8.69-9.38-21.46
Net Income
-18.67-15.8-8.96-8.69-9.38-21.46
Preferred Dividends & Other Adjustments
----0.07-
Net Income to Common
-18.67-15.8-8.96-8.69-9.45-21.46
Net Income Growth
------
Shares Outstanding (Basic)
2100--
Shares Outstanding (Diluted)
2100--
Shares Change
485.24%710.69%411.86%---
EPS (Basic)
-8.52-14.80-68.02-337.46--
EPS (Diluted)
-8.52-14.80-68.02-337.46--
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBITDA
-19.05-16.19-9.43-9.27-9.15-5.96
D&A For EBITDA
0.10.10.10.10.10.1
EBIT
-19.15-16.29-9.53-9.38-9.26-6.06
SEC Filings: 10-K · 10-Q